,Biomarker,Cancer,Drug_response
0,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,ribociclib Sensitive: A1 - Approval  Ann Oncol - 5 days
1,No biomarker No biomarker,Follicular Lymphoma Follicular Lymphoma,duvelisib Sensitive: A1 - Approval  PRNewswire - 1 day
2,No biomarker No biomarker,Chronic Lymphocytic Leukemia CLL,duvelisib Sensitive: A1 - Approval  PRNewswire - 1 day
3,RET fusion RET fusion,Non Small Cell Lung Cancer NSCLC,pralsetinib Sensitive: A1 - Approval  Lancet Oncol - 1 day
4,AXL positive AXL positive,Non Small Cell Lung Cancer NSCLC,BGB324 Sensitive: B - Late Trials  PRNewswire - 2 days
5,BIRC5 mutation BIRC5 mutation,Glioblastoma GBM,temozolomide Sensitive: D – Preclinical  Cell Mol Life Sci - 2 days
6,No biomarker No biomarker,Acute Myelogenous Leukemia AML,venetoclax Sensitive: A1 - Approval  PharmiWeb - 3 days
7,No biomarker No biomarker,Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma,capecitabine Sensitive: A2 - Guideline  Lancet - 3 days
8,FLT3-ITD mutation FLT3-ITD mutation,Acute Myelogenous Leukemia AML,gilteritinib + CUDC-907 Sensitive: D – Preclinical  Br J Cancer - 3 days
9,miR-27a-3p overexpression miR-27a-3p overexpression,Hepatocellular Cancer HCC,cisplatin Sensitive: D – Preclinical  Biosci Rep - 3 days
10,PD-L1 expression PD-L1 expression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,nivolumab Sensitive: B - Late Trials  Lancet - 5 days
11,PD-L1 expression PD-L1 expression,Gastric Cancer Gastric Cancer,nivolumab Sensitive: B - Late Trials  Lancet - 5 days
12,PD-L1 expression PD-L1 expression,Esophageal Adenocarcinoma Esophageal Adenocarcinoma,nivolumab Sensitive: B - Late Trials  Lancet - 5 days
13,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,durvalumab Sensitive: A1 - Approval  AstraZeneca Press Release - 6 days
14,No biomarker No biomarker,Renal Cell Carcinoma RCC,"nivolumab + cabozantinib tablet Sensitive: A1 - Approval  Exelixis, Inc - 6 days"
15,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,isatuximab-irfc Sensitive: A1 - Approval  Lancet - 6 days
16,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,Tyrosine kinase inhibitor Sensitive: B - Late Trials  J Neurosurg - 6 days
17,No biomarker No biomarker,B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia,brexucabtagene autoleucel Sensitive: B - Late Trials  Kite Pharma Press Release - 6 days
18,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: A1 - Approval  JAMA Oncol - 6 days
19,KRAS G12C KRAS G12C,Non Small Cell Lung Cancer NSCLC,sotorasib Sensitive: A1 - Approval  N Engl J Med - 6 days
20,RET fusion RET fusion,Non Small Cell Lung Cancer NSCLC,selpercatinib Sensitive: A1 - Approval  Clin Cancer Res - 6 days
21,BRAF V600 BRAF V600,Ganglioglioma Ganglioglioma,trametinib + dabrafenib Sensitive: C1 - Off-label  Neurology - 6 days
22,BRAF V600 BRAF V600,Glioma Glioma,trametinib + dabrafenib Sensitive: C1 - Off-label  Neurology - 6 days
23,BRAF V600 BRAF V600,Ganglioglioma Ganglioglioma,vemurafenib + cobimetinib Sensitive: C1 - Off-label  Neurology - 6 days
24,BRAF V600 BRAF V600,Glioma Glioma,vemurafenib + cobimetinib Sensitive: C1 - Off-label  Neurology - 6 days
25,ER mutation ER mutation,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,GDC-9545 Sensitive: C2 – Inclusion Criteria  Roche Press Release - 6 days
26,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,PCbTP Sensitive: C3 – Early Trials  Breast Cancer Res Treat - 6 days
27,EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression,Lung Adenocarcinoma LUAD,afatinib + atezolizumab Sensitive: C4 – Case Studies  Thorac Cancer - 6 days
28,No biomarker No biomarker,Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma,nivolumab + ipilimumab Sensitive: A1 - Approval  Bristol-Myers Squibb Press Release - 1 week
29,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,selinexor Sensitive: A1 - Approval  Karyopharm Press Release - 1 week
30,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,idecabtagene vicleucel Sensitive: A1 - Approval  PRNewswire - 1 week
31,No biomarker No biomarker,Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer,sintilimab Sensitive: A1 - Approval  PRNewswire - 1 week
32,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,pomalidomide + daratumumab/hyaluronidase Sensitive: B - Late Trials  Lancet Oncol - 1 week
33,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,JNJ-64007957 Sensitive: B - Late Trials  J&J Press Release - 1 week
34,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,CS1001 Sensitive: B - Late Trials  CStone Pharma Press Release - 1 week
35,tTMB-H tTMB-H,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,pembrolizumab Sensitive: B - Late Trials  Ann Oncol - 1 week
36,tTMB-H tTMB-H,Gastric Cancer Gastric Cancer,pembrolizumab Sensitive: B - Late Trials  Ann Oncol - 1 week
37,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,osimertinib Sensitive: A1 - Approval  AstraZeneca Press Release - 1 week
38,EGFR T790M EGFR T790M,Non Small Cell Lung Cancer NSCLC,osimertinib Sensitive: A1 - Approval  EACR 2021 - 1 week
39,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab + tucatinib Sensitive: A1 - Approval  Seagen Press Release - 1 week
40,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,osimertinib Sensitive: A1 - Approval  AstraZeneca Press Release - 1 week
41,PD-L1 overexpression PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,atezolizumab Sensitive: A1 - Approval  NICE - 1 week
42,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,ado-trastuzumab emtansine Sensitive: A1 - Approval  J Clin Oncol - 1 week
43,FGFR2 rearrangement FGFR2 rearrangement,Cholangiocarcinoma Cholangiocarcinoma,infigratinib Sensitive: A1 - Approval  FDA - 1 week
44,FGFR2 fusion FGFR2 fusion,Cholangiocarcinoma Cholangiocarcinoma,infigratinib Sensitive: A1 - Approval  FDA - 1 week
45,BRCA1 mutation BRCA1 mutation,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,olaparib Sensitive: A1 - Approval  N Engl J Med - 1 week
46,BRCA2 mutation BRCA2 mutation,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,olaparib Sensitive: A1 - Approval  N Engl J Med - 1 week
47,BRAF V600 BRAF V600,Melanoma Melanoma,trametinib + dabrafenib Sensitive: A1 - Approval  Cancer Chemother Pharmacol - 1 week
48,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,nivolumab Sensitive: B - Late Trials  N Engl J Med - 1 week
49,RET fusion RET fusion,Lung Adenocarcinoma LUAD,pralsetinib Sensitive: C1 - Off-label  Clin Cancer Res - 1 week
50,FGFR2 fusion FGFR2 fusion,Cholangiocarcinoma Cholangiocarcinoma,ARQ 087 Sensitive: C2 – Inclusion Criteria  Basilea Press Release - 1 week
51,BRAF mutation BRAF mutation,Melanoma Melanoma,encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria  Melanoma Res - 1 week
52,MAGEA4 expression MAGEA4 expression,Sarcoma Sarcoma,ADP-A2M4 Sensitive: C2 – Inclusion Criteria  J Clin Oncol - 1 week
53,IDH2 mutation IDH2 mutation,Glioma Glioma,AG-881 Sensitive: C2 – Inclusion Criteria  Clin Cancer Res - 1 week
54,IDH1 mutation IDH1 mutation,Glioma Glioma,AG-881 Sensitive: C2 – Inclusion Criteria  Clin Cancer Res - 1 week
55,CDKN2A mutation CDKN2A mutation,Urothelial Cancer Urothelial Cancer,Immunotherapy Resistant: C3 – Early Trials  Clin Cancer Res - 1 week
56,BCR-ABL1 fusion BCR-ABL1 fusion,Acute Lymphocytic Leukemia ALL,ponatinib + blinatumomab Sensitive: C3 – Early Trials  J Clin Oncol - 1 week
57,KMT2A rearrangement KMT2A rearrangement,Acute Myelogenous Leukemia AML,gemtuzumab ozogamicin Sensitive: C3 – Early Trials  J Clin Oncol - 1 week
58,CDCA3 overexpression CDCA3 overexpression,Non Small Cell Lung Cancer NSCLC,carboplatin Sensitive: C3 – Early Trials  Commun Biol - 1 week
59,CDCA3 overexpression CDCA3 overexpression,Non Small Cell Lung Cancer NSCLC,cisplatin Sensitive: C3 – Early Trials  Commun Biol - 1 week
60,ER overexpression ER overexpression,Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer,tamoxifen Resistant: C3 – Early Trials  Breast Cancer - 1 week
61,IDH2 mutation + ALK fusion IDH2 mutation + ALK fusion,Non Small Cell Lung Cancer NSCLC,ALK inhibitor Resistant: C3 – Early Trials  Mol Oncol - 1 week
62,PIK3CA mutation + ALK fusion PIK3CA mutation + ALK fusion,Non Small Cell Lung Cancer NSCLC,ALK inhibitor Resistant: C3 – Early Trials  Mol Oncol - 1 week
63,ALK fusion + ALK G1202R ALK fusion + ALK G1202R,Non Small Cell Lung Cancer NSCLC,ALK inhibitor Resistant: C3 – Early Trials  Mol Oncol - 1 week
64,ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L,Non Small Cell Lung Cancer NSCLC,ALK inhibitor Resistant: C3 – Early Trials  Mol Oncol - 1 week
65,ALK fusion + ALK G1269A ALK fusion + ALK G1269A,Non Small Cell Lung Cancer NSCLC,ALK inhibitor Resistant: C3 – Early Trials  Mol Oncol - 1 week
66,PD-L1 expression PD-L1 expression,Triple Negative Breast Cancer Triple Negative Breast Cancer,pembrolizumab + eribulin mesylate Sensitive: C3 – Early Trials  Clin Cancer Res - 1 week
67,MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression,Neuroendocrine Tumor Neuroendocrine Tumor,Immunotherapy Sensitive: C3 – Early Trials  Cancer Med - 1 week
68,HER-2 negative HER-2 negative,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials  Anticancer Res - 1 week
69,AR elevation AR elevation,Prostate Cancer Prostate Cancer,docetaxel Sensitive: C3 – Early Trials  Eur J Cancer - 1 week
70,DDR DDR,Soft Tissue Sarcoma Soft Tissue Sarcoma,olaparib Sensitive: C3 – Early Trials  EACR 2021 - 1 week
71,SAMHD1 expression SAMHD1 expression,Ovarian Cancer Ovarian Cancer,Platinum alkylating agent Resistant: C3 – Early Trials  EACR 2021 - 1 week
72,SAMHD1 expression SAMHD1 expression,Non Small Cell Lung Cancer NSCLC,Platinum alkylating agent Resistant: C3 – Early Trials  EACR 2021 - 1 week
73,SAMHD1 expression SAMHD1 expression,Breast Cancer Breast Cancer,capecitabine Resistant: C3 – Early Trials  EACR 2021 - 1 week
74,SAMHD1 expression SAMHD1 expression,Ovarian Cancer Ovarian Cancer,gemcitabine Resistant: C3 – Early Trials  EACR 2021 - 1 week
75,SAMHD1 expression SAMHD1 expression,Ovarian Cancer Ovarian Cancer,Platinum alkylating agent + gemcitabine Resistant: C3 – Early Trials  EACR 2021 - 1 week
76,ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion,Non Small Cell Lung Cancer NSCLC,crizotinib Resistant: C4 – Case Studies  Mol Oncol - 1 week
77,MSI-H/dMMR + TMB-H + PD-L1 overexpression MSI-H/dMMR + TMB-H + PD-L1 overexpression,Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma,pembrolizumab Sensitive: C4 – Case Studies  Dovepress - 1 week
78,AFP elevation + VIM positive AFP elevation + VIM positive,Sarcoma Sarcoma,doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies  Intern Med - 1 week
79,PD-L1 overexpression + MET exon 14 mutation PD-L1 overexpression + MET exon 14 mutation,Lung Adenocarcinoma LUAD,crizotinib Sensitive: C4 – Case Studies  Lung Cancer - 1 week
80,HR positive HR positive,Ovarian Cancer Ovarian Cancer,cisplatin Sensitive: D – Preclinical  Biosci Rep - 1 week
81,miR-34a expression miR-34a expression,Triple Negative Breast Cancer Triple Negative Breast Cancer,selinexor Sensitive: D – Preclinical  Pharmaceuticals (Basel) - 1 week
82,HOXA11 overexpression HOXA11 overexpression,Acute Myelogenous Leukemia AML,cytarabine Sensitive: D – Preclinical  Oncol Rep - 1 week
83,EGFR L747P EGFR L747P,Lung Adenocarcinoma LUAD,afatinib Sensitive: D – Preclinical  Clin Cancer Res - 1 week
84,EGFR exon 19 deletion + BRAF G464A EGFR exon 19 deletion + BRAF G464A,Lung Adenocarcinoma LUAD,trametinib + dabrafenib Sensitive: D – Preclinical  Clin Cancer Res - 1 week
85,PD-L2 overexpression PD-L2 overexpression,Endometrial Cancer Endometrial Cancer,paclitaxel Sensitive: D – Preclinical  EACR 2021 - 1 week
86,ATM underexpression ATM underexpression,Prostate Cancer Prostate Cancer,PARP inhibitor Sensitive: D – Preclinical  EACR 2021 - 1 week
87,BRCA1 underexpression BRCA1 underexpression,Prostate Cancer Prostate Cancer,PARP inhibitor Sensitive: D – Preclinical  EACR 2021 - 1 week
88,CYP3A4 overexpression CYP3A4 overexpression,Soft Tissue Sarcoma Soft Tissue Sarcoma,vincristine Resistant: D – Preclinical  EACR 2021 - 1 week
89,CYP3A5 underexpression CYP3A5 underexpression,Soft Tissue Sarcoma Soft Tissue Sarcoma,cyclophosphamide intravenous Resistant: D – Preclinical  EACR 2021 - 1 week
90,CD133 positive CD133 positive,Glioblastoma GBM,SY‑079 + CYC065 Sensitive: D – Preclinical  EACR 2021 - 1 week
91,BRCA2 underexpression BRCA2 underexpression,Prostate Cancer Prostate Cancer,PARP inhibitor Sensitive: D – Preclinical  EACR 2021 - 1 week
92,EPAS1 overexpression EPAS1 overexpression,Hepatocellular Cancer HCC,sorafenib Resistant: D – Preclinical  EACR 2021 - 1 week
93,CD44 positive CD44 positive,Glioblastoma GBM,SY‑079 + CYC065 Sensitive: D – Preclinical  EACR 2021 - 1 week
94,HER-2 exon 20 insertion HER-2 exon 20 insertion,Lung Adenocarcinoma LUAD,HM 78136B Sensitive: D – Preclinical  Clin Cancer Res - 1 week
95,ATRX mutation ATRX mutation,Glioblastoma GBM,selumetinib Sensitive: D – Preclinical  AACE 2021 - 1 week
96,HIF1A overexpression HIF1A overexpression,Hepatocellular Cancer HCC,sorafenib Resistant: D – Preclinical  EACR 2021 - 1 week
97,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,pertuzumab + Herzuma (trastuzumab biosimilar) Sensitive: D – Preclinical  EACR 2021 - 1 week
98,BST1 positive BST1 positive,Acute Myelogenous Leukemia AML,S63845 Sensitive: D – Preclinical  EACR 2021 - 1 week
99,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,melphalan flufenamide Sensitive: A1 - Approval  Oncopeptides Press Release - 2 weeks
100,No biomarker No biomarker,Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer,sintilimab Sensitive: A1 - Approval  J Thorac Oncol - 2 weeks
101,PD-L1 overexpression PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: A2 - Guideline  J Thorac Oncol - 2 weeks
102,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,EGFR inhibitor Sensitive: A2 - Guideline  BMC Cancer - 2 weeks
103,HER-2 Negative + PD-L1 expression HER-2 Negative + PD-L1 expression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,pembrolizumab Sensitive: A2 - Guideline  Merck (MSD) Press Release - 2 weeks
104,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,LCAR-B38M Sensitive: B - Late Trials  Legend Biotech - 2 weeks
105,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,gefitinib + rivoceranib Sensitive: B - Late Trials  J Thorac Oncol - 2 weeks
106,No biomarker No biomarker,Myelodysplastic Syndrome MDS,Hypomethylating agent + MBG453 Sensitive: B - Late Trials  Novartis Press Release - 2 weeks
107,No biomarker No biomarker,Ovarian Cancer Ovarian Cancer,VS-6766 + VS-6063 Sensitive: B - Late Trials  Verastem Press Release - 2 weeks
108,Chr amplification(1)(q21) Chr amplification(1)(q21),Multiple Myeloma Multiple Myeloma,pomalidomide + isatuximab-irfc Sensitive: B - Late Trials  Br J Haematol - 2 weeks
109,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab + pertuzumab Sensitive: A1 - Approval  Postgrad Med - 2 weeks
110,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval  NICE - 2 weeks
111,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,tepotinib Sensitive: A1 - Approval  Jpn J Clin Oncol - 2 weeks
112,PD-L1 overexpression PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,cemiplimab Sensitive: A1 - Approval  Regeneron Pharmaceuticals Press Release - 2 weeks
113,MSI-H/dMMR MSI-H/dMMR,Colorectal Cancer CRC,nivolumab + ipilimumab Sensitive: A1 - Approval  Bristol-Myers Squibb Press Release - 2 weeks
114,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,palbociclib Sensitive: A1 - Approval  Oncologist - 2 weeks
115,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,neratinib Sensitive: A1 - Approval  The Oncologist - 2 weeks
116,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,amivantamab-vmjw Sensitive: A1 - Approval  FDA - 2 weeks
117,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,pembrolizumab Sensitive: A1 - Approval  Lancet Oncol - 2 weeks
118,ALK rearrangement ALK rearrangement,Non Small Cell Lung Cancer NSCLC,lorlatinib Sensitive: A2 - Guideline  Transl Oncol - 2 weeks
119,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,pyrotinib Sensitive: B - Late Trials  Front Oncol - 2 weeks
120,PD-L1 expression PD-L1 expression,Esophageal Cancer Esophageal Cancer,pembrolizumab Sensitive: B - Late Trials  Merck (MSD) Press Release - 2 weeks
121,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria  NPJ Breast Cancer - 2 weeks
122,HER-2 negative HER-2 negative,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,rivoceranib Sensitive: C2 – Inclusion Criteria  Cancer Biol Med - 2 weeks
123,KRAS mutation KRAS mutation,Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer,binimetinib Sensitive: C2 – Inclusion Criteria  Lung Cancer - 2 weeks
124,BRCA1 deletion BRCA1 deletion,Prostate Cancer Prostate Cancer,rucaparib Sensitive: C3 – Early Trials  Cancer Discov - 2 weeks
125,BRCA2 deletion BRCA2 deletion,Prostate Cancer Prostate Cancer,olaparib Sensitive: C3 – Early Trials  Cancer Discov - 2 weeks
126,BTK C481S BTK C481S,Chronic Lymphocytic Leukemia CLL,ibrutinib Resistant: C3 – Early Trials  Br J Haematol - 2 weeks
127,HRD HRD,Ovarian Cancer Ovarian Cancer,PARP inhibitor Sensitive: C3 – Early Trials  Arch Gynecol Obstet - 2 weeks
128,CD24 overexpression CD24 overexpression,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,R-CHOP Sensitive: C3 – Early Trials  Dovepress - 2 weeks
129,MMP11 overexpression MMP11 overexpression,Breast Cancer Breast Cancer,GDC-0941 + AZ 960 Sensitive: C3 – Early Trials  PLoS One - 2 weeks
130,PALB2 deletion PALB2 deletion,Prostate Cancer Prostate Cancer,olaparib Sensitive: C3 – Early Trials  Cancer Discov - 2 weeks
131,ATM deletion ATM deletion,Prostate Cancer Prostate Cancer,olaparib Sensitive: C3 – Early Trials  Cancer Discov - 2 weeks
132,NRAS mutation NRAS mutation,Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer,binimetinib Sensitive: C3 – Early Trials  Lung Cancer - 2 weeks
133,PD-L1-H PD-L1-H,Bladder Cancer Bladder Cancer,Immunotherapy Resistant: C3 – Early Trials  Cancers (Basel) - 2 weeks
134,Chr t(4;9;22)(q21;q34;q11.2) Chr t(4;9;22)(q21;q34;q11.2),Chronic Myeloid Leukemia CML,dasatinib Sensitive: C4 – Case Studies  J Med Case Rep - 2 weeks
135,PDGFRA amplification + NTRK2 fusion PDGFRA amplification + NTRK2 fusion,Glioblastoma GBM,larotrectinib Resistant: C4 – Case Studies  Oncologist - 2 weeks
136,MLL-AFF1 fusion MLL-AFF1 fusion,Acute Lymphocytic Leukemia ALL,ONX 0914 Sensitive: D – Preclinical  Sci Rep - 2 weeks
137,FLT3-ITD mutation FLT3-ITD mutation,Acute Myelogenous Leukemia AML,Bcl2 inhibitor + Tyrosine kinase inhibitor Sensitive: D – Preclinical  Signal Transduct Target Ther - 2 weeks
138,HYAL4 V1 HYAL4 V1,Bladder Cancer Bladder Cancer,gemcitabine Resistant: D – Preclinical  Clin Cancer Res - 2 weeks
139,TET2 deletion + DNMT3A mutation TET2 deletion + DNMT3A mutation,Melanoma Melanoma,TdCyd Sensitive: D – Preclinical  J Hematol Oncol - 2 weeks
140,TET2 deletion + DNMT3A mutation TET2 deletion + DNMT3A mutation,Kidney Cancer Kidney Cancer,TdCyd Sensitive: D – Preclinical  J Hematol Oncol - 2 weeks
141,TET2 deletion + DNMT3A mutation TET2 deletion + DNMT3A mutation,Lung Cancer Lung Cancer,TdCyd Sensitive: D – Preclinical  J Hematol Oncol - 2 weeks
142,TET2 deletion + DNMT3A mutation TET2 deletion + DNMT3A mutation,Breast Cancer Breast Cancer,TdCyd Sensitive: D – Preclinical  J Hematol Oncol - 2 weeks
143,HYAL4 V1 HYAL4 V1,Bladder Cancer Bladder Cancer,gemcitabine + EPI01 Sensitive: D – Preclinical  Clin Cancer Res - 2 weeks
144,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,MEDI4276 Sensitive: D – Preclinical  Mol Cancer Ther - 2 weeks
145,miR-572 overexpression miR-572 overexpression,Prostate Cancer Prostate Cancer,docetaxel Resistant: D – Preclinical  J Int Med Res - 2 weeks
146,No biomarker No biomarker,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,nivolumab Sensitive: A1 - Approval  FDA - 3 weeks
147,No biomarker No biomarker,Esophageal Adenocarcinoma Esophageal Adenocarcinoma,nivolumab Sensitive: A1 - Approval  FDA - 3 weeks
148,No biomarker No biomarker,Urothelial Cancer Urothelial Cancer,enfortumab vedotin Sensitive: A1 - Approval  Astellas Press Release - 3 weeks
149,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,osimertinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
150,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,TCHP Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
151,HER-2 amplification HER-2 amplification,Colorectal Cancer CRC,trastuzumab + pertuzumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
152,No biomarker No biomarker,Glioma Glioma,temozolomide Sensitive: A2 - Guideline  Lancet Oncol - 3 weeks
153,No biomarker No biomarker,Marginal Zone Lymphoma Marginal Zone Lymphoma,zanubrutinib Sensitive: B - Late Trials  BeiGene Press Release - 3 weeks
154,PD-L1 expression PD-L1 expression,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,nivolumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
155,KRAS G12C KRAS G12C,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
156,H3.3K27M H3.3K27M,Glioma Glioma,ONC201 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
157,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,capecitabine + DJ 927 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
158,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,avelumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
159,KRAS mutation KRAS mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
160,No biomarker No biomarker,Thyroid Gland Carcinoma Thyroid Gland Carcinoma,AIC100 Sensitive: B - Late Trials  PRNewswire - 3 weeks
161,RAD51D mutation RAD51D mutation,Ovarian Cancer Ovarian Cancer,rucaparib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
162,RAD51C mutation RAD51C mutation,Ovarian Cancer Ovarian Cancer,rucaparib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
163,AR amplification AR amplification,Prostate Cancer Prostate Cancer,AST-2970 Resistant: B - Late Trials  J Natl Compr Canc Netw - 3 weeks
164,No biomarker No biomarker,Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma,AIC100 Sensitive: B - Late Trials  PRNewswire - 3 weeks
165,GRM1 overexpression GRM1 overexpression,Liposarcoma Liposarcoma,selinexor Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
166,CALB1 underexpression CALB1 underexpression,Liposarcoma Liposarcoma,selinexor Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
167,CCL11 overexpression CCL11 overexpression,Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma,tertomotide Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
168,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,oral paclitaxel/encequidar Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
169,PIK3CA N345K + N1044K PIK3CA N345K + N1044K,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
170,PIK3CA G106_108del PIK3CA G106_108del,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
171,PIK3CA R38C PIK3CA R38C,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
172,PIK3CA Q75E PIK3CA Q75E,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
173,PIK3CA N345K PIK3CA N345K,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
174,KIT mutation KIT mutation,Gastrointestinal Stromal Tumor GIST,TAS-116 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
175,KRAS mutation KRAS mutation,Ovarian Cancer Ovarian Cancer,binimetinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
176,TMB-L + LDH elevation TMB-L + LDH elevation,Melanoma Melanoma,vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
177,High IFNG gene signature High IFNG gene signature,Melanoma Melanoma,vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
178,TMB-H + LDH elevation TMB-H + LDH elevation,Melanoma Melanoma,vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
179,BCOR mutation BCOR mutation,Acute Myelogenous Leukemia AML,azacitidine Resistant: B - Late Trials  Cancers (Basel) - 3 weeks
180,PD-L1 expression PD-L1 expression,Triple Negative Breast Cancer Triple Negative Breast Cancer,atezolizumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
181,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,trastuzumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
182,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,nivolumab + ipilimumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
183,ALK positive ALK positive,Non Small Cell Lung Cancer NSCLC,brigatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
184,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,dacomitinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
185,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,dacomitinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
186,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,capmatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
187,FLT3 mutation FLT3 mutation,Acute Myelogenous Leukemia AML,gilteritinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
188,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,atezolizumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
189,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,afatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
190,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
191,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
192,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,erlotinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
193,MSI-H/dMMR MSI-H/dMMR,Colorectal Cancer CRC,pembrolizumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
194,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
195,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,pembrolizumab + trastuzumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
196,BRAF V600E BRAF V600E,Colorectal Cancer CRC,cetuximab + encorafenib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
197,PD-L1 expression PD-L1 expression,Squamous Cell Carcinoma of Head and Neck SCCHN,pembrolizumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
198,RET mutation RET mutation,Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma,selpercatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
199,MSI-H/dMMR MSI-H/dMMR,Solid Tumor Solid Tumor,pembrolizumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
200,HER-2 overexpression HER-2 overexpression,Gastric Cancer Gastric Cancer,trastuzumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
201,RET fusion RET fusion,Thyroid Gland Carcinoma Thyroid Gland Carcinoma,selpercatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
202,BRCA1 mutation BRCA1 mutation,Ovarian Cancer Ovarian Cancer,rucaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
203,BRCA2 mutation BRCA2 mutation,Ovarian Cancer Ovarian Cancer,rucaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
204,PIK3CA mutation + HR positive PIK3CA mutation + HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,alpelisib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
205,BRCA1 mutation BRCA1 mutation,Ovarian Cancer Ovarian Cancer,bevacizumab + olaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
206,BRCA2 mutation BRCA2 mutation,Ovarian Cancer Ovarian Cancer,bevacizumab + olaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
207,MSI-H/dMMR MSI-H/dMMR,Endometrial Cancer Endometrial Cancer,dostarlimab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
208,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,everolimus Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
209,BRCA1 mutation BRCA1 mutation,Ovarian Cancer Ovarian Cancer,olaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
210,BRCA2 mutation BRCA2 mutation,Ovarian Cancer Ovarian Cancer,olaparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
211,BRCA1 mutation BRCA1 mutation,Ovarian Cancer Ovarian Cancer,niraparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
212,BRCA2 mutation BRCA2 mutation,Ovarian Cancer Ovarian Cancer,niraparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
213,BRCA2 mutation BRCA2 mutation,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,talazoparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
214,BRCA1 mutation BRCA1 mutation,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,talazoparib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
215,BRAF V600 BRAF V600,Melanoma Melanoma,encorafenib + binimetinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
216,HRD HRD,Ovarian Cancer Ovarian Cancer,niraparib Sensitive: A1 - Approval  J Ovarian Res - 3 weeks
217,EZH2 mutation EZH2 mutation,Follicular Lymphoma Follicular Lymphoma,tazemetostat Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
218,FGFR2 rearrangement FGFR2 rearrangement,Cholangiocarcinoma Cholangiocarcinoma,pemigatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
219,FGFR2 fusion FGFR2 fusion,Cholangiocarcinoma Cholangiocarcinoma,pemigatinib Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
220,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,pembrolizumab + trastuzumab Sensitive: A1 - Approval  ASCO 2021 - 3 weeks
221,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,atezolizumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
222,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,trastuzumab Sensitive: A2 - Guideline  Oncologist - 3 weeks
223,ALK rearrangement ALK rearrangement,Non Small Cell Lung Cancer NSCLC,alectinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
224,IDH1 mutation IDH1 mutation,Cholangiocarcinoma Cholangiocarcinoma,ivosidenib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
225,ALK rearrangement ALK rearrangement,Non Small Cell Lung Cancer NSCLC,ceritinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
226,TMB-H TMB-H,Gastric Cancer Gastric Cancer,pembrolizumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
227,ALK rearrangement ALK rearrangement,Non Small Cell Lung Cancer NSCLC,brigatinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
228,HR positive HR positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
229,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,lapatinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
230,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,bevacizumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
231,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,crizotinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
232,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,icotinib Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
233,MSI-H/dMMR MSI-H/dMMR,Gastric Cancer Gastric Cancer,pembrolizumab Sensitive: A2 - Guideline  ASCO 2021 - 3 weeks
234,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,TAK-788 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
235,PIK3CA mutation PIK3CA mutation,Breast Cancer Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
236,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab + pyrotinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
237,ER positive ER positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,palbociclib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
238,BRAF mutation BRAF mutation,Melanoma Melanoma,nivolumab + ipilimumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
239,KRAS mutation KRAS mutation,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
240,HRD HRD,Ovarian Cancer Ovarian Cancer,olaparib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
241,HER-2 amplification HER-2 amplification,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,trastuzumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
242,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,alpelisib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
243,HRAS mutation HRAS mutation,Squamous Cell Carcinoma of Head and Neck SCCHN,tipifarnib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
244,DNMT3A mutation DNMT3A mutation,Acute Myelogenous Leukemia AML,azacitidine Resistant: B - Late Trials  Cancers (Basel) - 3 weeks
245,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,Ogivri (trastuzumab biosimilar) Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
246,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,SHR6390 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
247,FOLH1 positive FOLH1 positive,Prostate Cancer Prostate Cancer,177 Lu PSMA-617 Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
248,PD-L1 expression PD-L1 expression,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,nivolumab + ipilimumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
249,UGT1A1*1*1 UGT1A1*1*1,Rectal Cancer Rectal Cancer,capecitabine + irinotecan Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
250,HER-2 negative HER-2 negative,Breast Cancer Breast Cancer,abemaciclib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
251,HR positive HR positive,Breast Cancer Breast Cancer,abemaciclib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
252,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,almonertinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
253,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,almonertinib Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
254,PD-L1 expression PD-L1 expression,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,tislelizumab Sensitive: B - Late Trials  ASCO 2021 - 3 weeks
255,NRAS mutation NRAS mutation,Acute Myelogenous Leukemia AML,azacitidine Resistant: B - Late Trials  Cancers (Basel) - 3 weeks
256,EZH2 mutation EZH2 mutation,Acute Myelogenous Leukemia AML,azacitidine Sensitive: B - Late Trials  Cancers (Basel) - 3 weeks
257,EGFR mutation EGFR mutation,Lung Adenocarcinoma LUAD,bevacizumab + erlotinib Sensitive: C1 - Off-label  Oncol Ther - 3 weeks
258,RET fusion RET fusion,Pancreatic Cancer Pancreatic Cancer,pralsetinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
259,RET fusion RET fusion,Cholangiocarcinoma Cholangiocarcinoma,pralsetinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
260,MSI-H/dMMR MSI-H/dMMR,Gastric Cancer Gastric Cancer,nivolumab Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
261,EGFR exon 19 deletion EGFR exon 19 deletion,Lung Adenocarcinoma LUAD,osimertinib Resistant: C1 - Off-label  ASCO 2021 - 3 weeks
262,BRCA2 mutation BRCA2 mutation,Triple Negative Breast Cancer Triple Negative Breast Cancer,BGB-290 Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
263,BRCA1 mutation BRCA1 mutation,Triple Negative Breast Cancer Triple Negative Breast Cancer,BGB-290 Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
264,EGFR L858R EGFR L858R,Lung Adenocarcinoma LUAD,osimertinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
265,NTRK1 fusion NTRK1 fusion,Lung Cancer Lung Cancer,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
266,BRCA2 mutation BRCA2 mutation,Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma,olaparib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
267,NTRK3 fusion NTRK3 fusion,Lung Cancer Lung Cancer,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
268,IDH2 mutation IDH2 mutation,Myelodysplastic Syndrome MDS,enasidenib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
269,TMB-H TMB-H,Urothelial Cancer Urothelial Cancer,pembrolizumab Sensitive: C1 - Off-label  J Oncol Pharm Pract - 3 weeks
270,EGFR exon 19 deletion EGFR exon 19 deletion,Lung Cancer Lung Cancer,gefitinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
271,BRCA1 mutation BRCA1 mutation,Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma,olaparib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
272,EGFR mutation EGFR mutation,Gastric Cancer Gastric Cancer,afatinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
273,BRAF V600E BRAF V600E,Gastric Cancer Gastric Cancer,vemurafenib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
274,PD-L1 expression PD-L1 expression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,durvalumab Resistant: C1 - Off-label  ASCO 2021 - 3 weeks
275,EGFR mutation EGFR mutation,Lung Cancer Lung Cancer,gefitinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
276,RET fusion RET fusion,Salivary Gland Cancer Salivary Gland Cancer,pralsetinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
277,NTRK3 fusion NTRK3 fusion,Glioma Glioma,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
278,NTRK2 fusion NTRK2 fusion,Glioma Glioma,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
279,NTRK1 fusion NTRK1 fusion,Glioma Glioma,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
280,NTRK3 fusion NTRK3 fusion,CNS Tumor CNS Tumor,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
281,NTRK2 fusion NTRK2 fusion,CNS Tumor CNS Tumor,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
282,NTRK1 fusion NTRK1 fusion,CNS Tumor CNS Tumor,larotrectinib Sensitive: C1 - Off-label  ASCO 2021 - 3 weeks
283,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,cetuximab + afatinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
284,EGFR exon 19 mutation EGFR exon 19 mutation,Non Small Cell Lung Cancer NSCLC,erlotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
285,ALK translocation ALK translocation,Non Small Cell Lung Cancer NSCLC,durvalumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
286,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,durvalumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
287,PD-L1 overexpression PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,durvalumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
288,PD-L1 expression PD-L1 expression,Gastric Cancer Gastric Cancer,pembrolizumab + lenvatinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
289,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,U3-1402 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
290,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,anlotinib + icotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
291,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,anlotinib + icotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
292,ER positive ER positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,G1T48 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
293,ER Y537S ER Y537S,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,H3B-6545 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
294,ER positive ER positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,H3B-6545 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
295,HER-2 expression HER-2 expression,Colorectal Cancer CRC,fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
296,CD20 positive CD20 positive,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,GEN3013 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
297,CD20 positive CD20 positive,Follicular Lymphoma Follicular Lymphoma,GEN3013 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
298,PD-L1 expression PD-L1 expression,Melanoma Melanoma,toripalimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
299,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,HM 78136B Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
300,HER-2 overexpression HER-2 overexpression,Gastric Cancer Gastric Cancer,RC48 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
301,HER-2 exon 20 insertion HER-2 exon 20 insertion,Non Small Cell Lung Cancer NSCLC,HM 78136B Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
302,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,pyrotinib + SHR6390 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
303,HER-2 mutation HER-2 mutation,Non Small Cell Lung Cancer NSCLC,trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
304,FGFR2 overexpression FGFR2 overexpression,Gastric Cancer Gastric Cancer,FPA-144 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
305,MET amplification MET amplification,Gastric Cancer Gastric Cancer,HMPL-504 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
306,EGFR exon 21 mutation EGFR exon 21 mutation,Non Small Cell Lung Cancer NSCLC,erlotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
307,HER-2 expression HER-2 expression,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,A166 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
308,BCR-ABL1 fusion BCR-ABL1 fusion,Acute Lymphocytic Leukemia ALL,bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria  Am J Hematol - 3 weeks
309,MSI-H/dMMR MSI-H/dMMR,Solid Tumor Solid Tumor,tislelizumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
310,EGFR T790M EGFR T790M,Non Small Cell Lung Cancer NSCLC,AST2818 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
311,EGFR negative EGFR negative,Non Small Cell Lung Cancer NSCLC,anlotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
312,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,eribulin mesylate Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
313,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
314,BRAF V600E BRAF V600E,Colorectal Cancer CRC,bevacizumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
315,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,rivoceranib + camrelizumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
316,PD-L1 expression PD-L1 expression,Cervical Cancer Cervical Cancer,HLX10 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
317,HER-2 overexpression HER-2 overexpression,Urothelial Cancer Urothelial Cancer,RC48 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
318,POLE mutation POLE mutation,Colorectal Cancer CRC,nivolumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
319,TMB-H TMB-H,Gastric Cancer Gastric Cancer,sintilimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
320,MSI-H/dMMR MSI-H/dMMR,Gastric Cancer Gastric Cancer,tislelizumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
321,FGFR2b overexpression FGFR2b overexpression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,FPA-144 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
322,ER D538G ER D538G,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,H3B-6545 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
323,SSTR positive SSTR positive,Neuroendocrine Tumor Neuroendocrine Tumor,lutetium Lu 177 dotatate Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
324,SSTR2 positive SSTR2 positive,Neuroendocrine Tumor Neuroendocrine Tumor,PEN-221 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
325,EGFR L861Q EGFR L861Q,Non Small Cell Lung Cancer NSCLC,dacomitinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
326,MGMT promoter methylation MGMT promoter methylation,Ewing Sarcoma Ewing Sarcoma,temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
327,MSI-H/dMMR MSI-H/dMMR,Rectal Cancer Rectal Cancer,sintilimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
328,HER-2 positive HER-2 positive,Solid Tumor Solid Tumor,pyrotinib + SHR6390 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
329,ROS1 rearrangement ROS1 rearrangement,Lung Cancer Lung Cancer,crizotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
330,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,durvalumab + MEDI9447 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
331,ROS1 fusion ROS1 fusion,Non Small Cell Lung Cancer NSCLC,AB106 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
332,RET mutation RET mutation,Non Small Cell Lung Cancer NSCLC,BOS-172738 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
333,RET mutation RET mutation,Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma,BOS-172738 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
334,NRG1 fusion NRG1 fusion,Pancreatic Cancer Pancreatic Cancer,MCLA-128 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
335,MSI-H/dMMR MSI-H/dMMR,Solid Tumor Solid Tumor,HX008 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
336,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,INCMGA0012 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
337,PD-L1 overexpression PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,INCMGA0012 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
338,MSI-H/dMMR MSI-H/dMMR,Solid Tumor Solid Tumor,HLX10 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
339,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,cemiplimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
340,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,CLN-081 Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
341,EGFR mutation EGFR mutation,Lung Adenocarcinoma LUAD,osimertinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
342,ROS1 positive ROS1 positive,Non Small Cell Lung Cancer NSCLC,brigatinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
343,PD-L1 expression PD-L1 expression,Mucosal Melanoma Mucosal Melanoma,toripalimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
344,TMB-H TMB-H,Non Small Cell Lung Cancer NSCLC,sintilimab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
345,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
346,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
347,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,trastuzumab + ramucirumab Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
348,MET amplification MET amplification,Non Small Cell Lung Cancer NSCLC,tepotinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
349,BRAF V600 BRAF V600,Melanoma Melanoma,pembrolizumab + encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
350,BRAF mutation BRAF mutation,Melanoma Melanoma,nivolumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
351,BRAF V600 BRAF V600,Melanoma Melanoma,lifileucel Sensitive: C2 – Inclusion Criteria  ASCO 2021 - 3 weeks
352,IDH1 mutation IDH1 mutation,Cholangiocarcinoma Cholangiocarcinoma,metformin Sensitive: C2 – Inclusion Criteria  Cancers (Basel) - 3 weeks
353,IDH1 mutation IDH1 mutation,Sarcoma Sarcoma,metformin Sensitive: C2 – Inclusion Criteria  Cancers (Basel) - 3 weeks
354,IDH1 mutation IDH1 mutation,Glioma Glioma,metformin Sensitive: C2 – Inclusion Criteria  Cancers (Basel) - 3 weeks
355,PD-L1 rs4143815 PD-L1 rs4143815,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  Tumori - 3 weeks
356,EGFR exon 20 insertion EGFR exon 20 insertion,Non Small Cell Lung Cancer NSCLC,cisplatin + pemetrexed Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
357,EGFR exon 19 mutation EGFR exon 19 mutation,Lung Adenocarcinoma LUAD,bevacizumab + erlotinib Sensitive: C3 – Early Trials  Oncol Ther - 3 weeks
358,EGFR L858R EGFR L858R,Lung Adenocarcinoma LUAD,bevacizumab + erlotinib Sensitive: C3 – Early Trials  Oncol Ther - 3 weeks
359,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
360,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,erlotinib + anlotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
361,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
362,HER-2 amplification HER-2 amplification,Non Small Cell Lung Cancer NSCLC,rivoceranib + pyrotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
363,BRAF mutation BRAF mutation,Melanoma Melanoma,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
364,PD-L1 expression PD-L1 expression,Squamous Cell Carcinoma of Head and Neck SCCHN,pembrolizumab + IMP 321 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
365,PD-L1 expression PD-L1 expression,Cholangiocarcinoma Cholangiocarcinoma,lenvatinib + toripalimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
366,IDH1 mutation IDH1 mutation,Acute Myelogenous Leukemia AML,venetoclax + ivosidenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
367,IDH1 mutation IDH1 mutation,Acute Myelogenous Leukemia AML,FT-2102 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
368,KRAS mutation KRAS mutation,Non Small Cell Lung Cancer NSCLC,PD-L1 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
369,NRAS Q61K NRAS Q61K,Melanoma Melanoma,trametinib + dabrafenib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
370,EGFR exon 18 mutation EGFR exon 18 mutation,Non Small Cell Lung Cancer NSCLC,neratinib Sensitive: C3 – Early Trials  - 3 weeks
371,STK11 mutation STK11 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
372,KEAP1 mutation KEAP1 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
373,KRAS mutation + SMARCA4 mutation KRAS mutation + SMARCA4 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
374,TMB-H TMB-H,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
375,EGFR T790M EGFR T790M,Non Small Cell Lung Cancer NSCLC,Tyrosine kinase inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
376,CDK4 amplification CDK4 amplification,Soft Tissue Sarcoma Soft Tissue Sarcoma,palbociclib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
377,PD-L1 expression PD-L1 expression,Cervical Cancer Cervical Cancer,anlotinib + sintilimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
378,TMB-H TMB-H,Colorectal Cancer CRC,nivolumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
379,BRAF mutation BRAF mutation,Melanoma Melanoma,dabrafenib + SNR1611 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
380,BRCA2 mutation BRCA2 mutation,Prostate Cancer Prostate Cancer,PARP inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
381,MET amplification MET amplification,Gastric Cancer Gastric Cancer,crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
382,FOLR1 overexpression FOLR1 overexpression,Ovarian Cancer Ovarian Cancer,bevacizumab + IMGN 853 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
383,HER-2 expression HER-2 expression,Salivary Gland Cancer Salivary Gland Cancer,fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
384,TMB-H TMB-H,Gastric Cancer Gastric Cancer,nivolumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
385,TP53 mutation TP53 mutation,Prostate Cancer Prostate Cancer,abiraterone acetate Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
386,CDK12 mutation CDK12 mutation,Prostate Cancer Prostate Cancer,AST-2970 Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
387,RB1 mutation RB1 mutation,Prostate Cancer Prostate Cancer,Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
388,AR amplification AR amplification,Prostate Cancer Prostate Cancer,docetaxel Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
389,RET fusion RET fusion,Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma,cabozantinib tablet Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
390,HER-2 positive HER-2 positive,Gastric Cancer Gastric Cancer,ARX788 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
391,KMT2D mutation KMT2D mutation,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
392,KMT2C mutation KMT2C mutation,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
393,IDH1 mutation IDH1 mutation,Myelodysplastic Syndrome MDS,venetoclax + ivosidenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
394,RB1 mutation RB1 mutation,Prostate Cancer Prostate Cancer,docetaxel Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
395,TP53 mutation TP53 mutation,Prostate Cancer Prostate Cancer,docetaxel Resistant: C3 – Early Trials  J Natl Compr Canc Netw - 3 weeks
396,IDH2 mutation IDH2 mutation,Acute Myelogenous Leukemia AML,SEL24 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
397,IDH1 mutation IDH1 mutation,Acute Myelogenous Leukemia AML,SEL24 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
398,FLT3-ITD mutation FLT3-ITD mutation,Acute Myelogenous Leukemia AML,FF-10101 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
399,SMAD4 deletion SMAD4 deletion,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials  Clin Transl Sci - 3 weeks
400,IGH mutation IGH mutation,Chronic Lymphocytic Leukemia CLL,iFCG Sensitive: C3 – Early Trials  Leukemia - 3 weeks
401,HRAS mutation HRAS mutation,Solid Tumor Solid Tumor,selumetinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
402,NRAS mutation NRAS mutation,Solid Tumor Solid Tumor,selumetinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
403,KRAS mutation KRAS mutation,Solid Tumor Solid Tumor,selumetinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
404,NF1 mutation NF1 mutation,Solid Tumor Solid Tumor,selumetinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
405,STK11 mutation + KEAP1 mutation STK11 mutation + KEAP1 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
406,EGFR exon 21 mutation EGFR exon 21 mutation,Non Small Cell Lung Cancer NSCLC,dacomitinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
407,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,gefitinib + anlotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
408,PTEN mutation + TP53 mutation PTEN mutation + TP53 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
409,TGFBR2 mutation TGFBR2 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
410,FGFR3 overexpression FGFR3 overexpression,Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer,BAY1163877 Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
411,FGFR2 overexpression FGFR2 overexpression,Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer,BAY1163877 Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
412,FGFR1 overexpression FGFR1 overexpression,Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer,BAY1163877 Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
413,ALK fusion ALK fusion,Non Small Cell Lung Cancer NSCLC,pemetrexed Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
414,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,erlotinib + anlotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
415,KEAP1 mutation + KRAS mutation KEAP1 mutation + KRAS mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
416,EGFR R776H EGFR R776H,Non Small Cell Lung Cancer NSCLC,osimertinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
417,LRP1B mutation + TMB-H LRP1B mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
418,TMB-H TMB-H,Glioblastoma GBM,nivolumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
419,KRAS mutation + STK11 mutation + KEAP1 mutation KRAS mutation + STK11 mutation + KEAP1 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
420,RNF43 mutation RNF43 mutation,Bladder Cancer Bladder Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
421,KRAS G12C + PD-L1 overexpression KRAS G12C + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
422,TMB-H TMB-H,Anaplastic Astrocytoma Anaplastic Astrocytoma,nivolumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
423,KMT2C mutation + TMB-H KMT2C mutation + TMB-H,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
424,TIMELESS P1018L TIMELESS P1018L,Colorectal Cancer CRC,bevacizumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
425,ATM mutation ATM mutation,Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma,durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
426,PD-L1 expression PD-L1 expression,Urothelial Cancer Urothelial Cancer,toripalimab + RC48 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
427,HER-2 expression HER-2 expression,Urothelial Cancer Urothelial Cancer,toripalimab + RC48 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
428,POLE mutation POLE mutation,Colorectal Cancer CRC,nivolumab + ipilimumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
429,MET mutation + TMB-H MET mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
430,TMB-H TMB-H,Gastric Cancer Gastric Cancer,tislelizumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
431,TPR mutation + TMB-H TPR mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
432,ERO1A overexpression ERO1A overexpression,Lung Adenocarcinoma LUAD,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
433,MSI-H/dMMR MSI-H/dMMR,Gastric Cancer Gastric Cancer,sintilimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
434,HER-2 mutation HER-2 mutation,Gastric Cancer Gastric Cancer,trastuzumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
435,HER-2 mutation HER-2 mutation,Gastric Cancer Gastric Cancer,RC48 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
436,MET overexpression MET overexpression,Gastric Cancer Gastric Cancer,crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
437,MET overexpression MET overexpression,Gastric Cancer Gastric Cancer,HMPL-504 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
438,BRAF mutation BRAF mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + dacarbazine Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
439,LDH-H LDH-H,Melanoma Melanoma,PD1 inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
440,PALB2 mutation + TMB-H + TNB-H PALB2 mutation + TMB-H + TNB-H,Melanoma Melanoma,PD-L1 inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
441,PALB2 mutation + TMB-H + TNB-H PALB2 mutation + TMB-H + TNB-H,Melanoma Melanoma,CTLA4 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
442,PALB2 mutation + TMB-H + TNB-H PALB2 mutation + TMB-H + TNB-H,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
443,LDH-H + BRAF mutation LDH-H + BRAF mutation,Melanoma Melanoma,PD1 inhibitor + CTLA4 inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
444,BRAF V600E BRAF V600E,Non Small Cell Lung Cancer NSCLC,Tyrosine kinase inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
445,BRCA2 mutation + TMB-H BRCA2 mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
446,BRCA1 mutation + TMB-H BRCA1 mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
447,BRAF V600E BRAF V600E,Non Small Cell Lung Cancer NSCLC,BRAF inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
448,EGFR G719X EGFR G719X,Non Small Cell Lung Cancer NSCLC,Tyrosine kinase inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
449,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,anlotinib + APL-502 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
450,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,anlotinib + APL-502 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
451,KIR2DL3 overexpression KIR2DL3 overexpression,Biliary Tract Cancer Biliary Tract Cancer,rivoceranib + camrelizumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
452,BRAF V600E + BRAF G469A + BRAF G469V BRAF V600E + BRAF G469A + BRAF G469V,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
453,IL1B overexpression IL1B overexpression,Biliary Tract Cancer Biliary Tract Cancer,rivoceranib + camrelizumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
454,Chr amplification(11p) Chr amplification(11p),Non Small Cell Lung Cancer NSCLC,CaT Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
455,Chr amplification(1p) Chr amplification(1p),Non Small Cell Lung Cancer NSCLC,CaT Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
456,CGAS overexpression + PD-L1 overexpression CGAS overexpression + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
457,BRAF mutation + PD-L1 overexpression BRAF mutation + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,BRAF inhibitor + Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
458,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,ARX788 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
459,KMT2C mutation KMT2C mutation,Hepatocellular Cancer HCC,PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
460,BRAF mutation BRAF mutation,Non Small Cell Lung Cancer NSCLC,trametinib + dabrafenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
461,miR-34a overexpression miR-34a overexpression,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
462,S100A8 overexpression S100A8 overexpression,Biliary Tract Cancer Biliary Tract Cancer,rivoceranib + camrelizumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
463,PTEN deletion PTEN deletion,Prostate Cancer Prostate Cancer,darolutamide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
464,PTEN deletion PTEN deletion,Prostate Cancer Prostate Cancer,apalutamide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
465,FGFR2b positive FGFR2b positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,FPA-144 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
466,BRCA2 mutation BRCA2 mutation,Pancreatic Cancer Pancreatic Cancer,FOLFIRINOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
467,BRCA1 mutation BRCA1 mutation,Pancreatic Cancer Pancreatic Cancer,FOLFIRINOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
468,TP53 mutation TP53 mutation,Biliary Tract Cancer Biliary Tract Cancer,toripalimab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
469,SMAD4 mutation SMAD4 mutation,Biliary Tract Cancer Biliary Tract Cancer,toripalimab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
470,CDKN2A mutation CDKN2A mutation,Biliary Tract Cancer Biliary Tract Cancer,toripalimab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
471,KRAS mutation KRAS mutation,Biliary Tract Cancer Biliary Tract Cancer,toripalimab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
472,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,abemaciclib + BI-836845 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
473,PD-L1 expression PD-L1 expression,Gastric Cancer Gastric Cancer,rivoceranib + toripalimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
474,CIP2A rs13069780 CIP2A rs13069780,Colorectal Cancer CRC,cetuximab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
475,PTPA rs2541164 PTPA rs2541164,Colorectal Cancer CRC,bevacizumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
476,ER negative + HER-2 negative ER negative + HER-2 negative,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,CDK6 inhibitor + CDK4 inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
477,PD-L1 expression PD-L1 expression,Colorectal Cancer CRC,pembrolizumab + lenvatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
478,ER positive ER positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,LY3484356 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
479,TMB-H TMB-H,Endometrial Cancer Endometrial Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
480,TMB-H TMB-H,Gastric Cancer Gastric Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
481,HR positive HR positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,pyrotinib + SHR6390 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
482,TP53 mutation TP53 mutation,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,SCT200 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
483,TP53 mutation TP53 mutation,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,FOLFIRINOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
484,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,FOLFIRI Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
485,BRCA2 mutation BRCA2 mutation,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,FOLFIRINOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
486,AR positive AR positive,Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer,enobosarm Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
487,TP53 mutation TP53 mutation,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,FOLFOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
488,BRCA2 mutation BRCA2 mutation,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,FOLFOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
489,CD8 positive CD8 positive,Triple Negative Breast Cancer Triple Negative Breast Cancer,camrelizumab + SHR 1020 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
490,DDR DDR,Hepatocellular Cancer HCC,FOLFOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
491,SPTA1 mutation SPTA1 mutation,Lung Adenocarcinoma LUAD,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
492,ER positive ER positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,venetoclax Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
493,CLDN18.2 overexpression CLDN18.2 overexpression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,IMAB362 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
494,CLDN18.2 overexpression CLDN18.2 overexpression,Gastric Cancer Gastric Cancer,IMAB362 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
495,PGP overexpression PGP overexpression,Osteosarcoma Osteosarcoma,ifosfamide + mifamurtide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
496,ITGAE overexpression ITGAE overexpression,Oropharyngeal Cancer Oropharyngeal Cancer,cetuximab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
497,FGFR3 expression FGFR3 expression,Urothelial Cancer Urothelial Cancer,atezolizumab + BAY1163877 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
498,FGFR1 expression FGFR1 expression,Urothelial Cancer Urothelial Cancer,atezolizumab + BAY1163877 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
499,BRCA1 mutation + BRCA2 mutation + TMB-H BRCA1 mutation + BRCA2 mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
500,NRAS mutation + BRAF mutation NRAS mutation + BRAF mutation,Colorectal Cancer CRC,nivolumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
501,BRCA2 mutation + HR positive BRCA2 mutation + HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,BGB-290 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
502,BRCA1 mutation + HR positive BRCA1 mutation + HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,BGB-290 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
503,FGFR2b positive FGFR2b positive,Gastric Cancer Gastric Cancer,FPA-144 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
504,PTPN11 mutation + TMB-H PTPN11 mutation + TMB-H,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
505,ACSL4 overexpression ACSL4 overexpression,Cutaneous Melanoma Cutaneous Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
506,MAP2K2 mutation MAP2K2 mutation,Melanoma Melanoma,CTLA4 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
507,MAP2K1 mutation MAP2K1 mutation,Melanoma Melanoma,CTLA4 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
508,RECQL5 mutation + TMB-H RECQL5 mutation + TMB-H,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
509,NRAS mutation NRAS mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + temozolomide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
510,KIT mutation KIT mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + temozolomide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
511,BRAF mutation BRAF mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + temozolomide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
512,NRAS mutation NRAS mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + dacarbazine Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
513,KIT mutation KIT mutation,Mucosal Melanoma Mucosal Melanoma,cisplatin + dacarbazine Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
514,KRAS mutation KRAS mutation,Colorectal Cancer CRC,pembrolizumab + selinexor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
515,MSI-L/dMMR MSI-L/dMMR,Colorectal Cancer CRC,camrelizumab + SHR7390 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
516,MSI-H/dMMR MSI-H/dMMR,Colorectal Cancer CRC,camrelizumab + SHR7390 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
517,BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR,Colorectal Cancer CRC,camrelizumab + SHR7390 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
518,MSI-H/dMMR MSI-H/dMMR,Colorectal Cancer CRC,fruquintinib + GB226 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
519,HER-2 positive HER-2 positive,Colorectal Cancer CRC,pyrotinib + SHR6390 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
520,NTRK3 fusion NTRK3 fusion,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
521,NTRK2 fusion NTRK2 fusion,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
522,NTRK1 fusion NTRK1 fusion,Colorectal Cancer CRC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
523,TYMS underexpression TYMS underexpression,Colorectal Cancer CRC,FOLFIRI Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
524,TYMS underexpression TYMS underexpression,Colorectal Cancer CRC,FOLFOX Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
525,SPTA1 mutation + KEAP1 mutation SPTA1 mutation + KEAP1 mutation,Lung Adenocarcinoma LUAD,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
526,CD163 expression CD163 expression,Anal Carcinoma Anal Carcinoma,toripalimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
527,CD4 expression CD4 expression,Anal Carcinoma Anal Carcinoma,toripalimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
528,PD-L1 expression PD-L1 expression,Anal Carcinoma Anal Carcinoma,toripalimab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
529,SSTR Expression SSTR Expression,Neuroendocrine Tumor Neuroendocrine Tumor,212Pb-labeled peptide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
530,HER-2 mutation + CDK6 mutation HER-2 mutation + CDK6 mutation,Ampulla of Vater Carcinoma Ampulla of Vater Carcinoma,palbociclib + pertuzumab + ribociclib + abemaciclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
531,FGFR2 F276C FGFR2 F276C,Cholangiocarcinoma Cholangiocarcinoma,pemigatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
532,FGFR1 A354V FGFR1 A354V,Esophageal Cancer Esophageal Cancer,pemigatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
533,POLE A456P POLE A456P,Colon Cancer Colon Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
534,SPARC overexpression SPARC overexpression,Ewing Sarcoma Ewing Sarcoma,albumin-bound paclitaxel Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
535,MET amplification MET amplification,Sarcoma Sarcoma,crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
536,BRAF D594N BRAF D594N,Gallbladder Cancer Gallbladder Cancer,encorafenib + binimetinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
537,BRAF G469S BRAF G469S,Melanoma Melanoma,encorafenib + binimetinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
538,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,SHR-1701 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
539,MDM2 amplification MDM2 amplification,Liposarcoma Liposarcoma,BI 907828 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
540,RET fusion RET fusion,Pancreatic Cancer Pancreatic Cancer,BOS-172738 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
541,NRAS mutation NRAS mutation,Melanoma Melanoma,cobimetinib + HM95573 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
542,ASNS deletion ASNS deletion,Ovarian Cancer Ovarian Cancer,IPN60090 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
543,POLE mutation POLE mutation,GastroEsophageal Cancer GastroEsophageal Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
544,POLD1 mutation POLD1 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
545,POLD1 mutation POLD1 mutation,GastroEsophageal Cancer GastroEsophageal Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
546,POLE mutation POLE mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
547,KMT2C mutation KMT2C mutation,Renal Cell Carcinoma RCC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
548,KMT2C mutation KMT2C mutation,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
549,KMT2C mutation KMT2C mutation,Bladder Cancer Bladder Cancer,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
550,MSI-H/dMMR MSI-H/dMMR,Colorectal Cancer CRC,HX008 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
551,KRAS G12V KRAS G12V,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
552,TAF15-CHN1 translocation TAF15-CHN1 translocation,Osteosarcoma Osteosarcoma,SP2577 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
553,EGFR amplification EGFR amplification,Squamous Cell Carcinoma of Head and Neck SCCHN,pembrolizumab + afatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
554,PD-L1 overexpression PD-L1 overexpression,Squamous Cell Carcinoma of Head and Neck SCCHN,pembrolizumab + afatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
555,PIK3CA amplification PIK3CA amplification,Chordoma Chordoma,everolimus Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
556,PIK3CA M1043I PIK3CA M1043I,Chordoma Chordoma,everolimus Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
557,SMARCB1 A240fsX28 SMARCB1 A240fsX28,Sarcoma Sarcoma,tazemetostat Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
558,FUS-DDIT3 translocation FUS-DDIT3 translocation,Liposarcoma Liposarcoma,SP2577 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
559,SMARCB1 A240fsX28 SMARCB1 A240fsX28,Sarcoma Sarcoma,palbociclib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
560,NF2 E108X NF2 E108X,Neurofibrosarcoma Neurofibrosarcoma,everolimus Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
561,NF2 E108X NF2 E108X,Neurofibrosarcoma Neurofibrosarcoma,temsirolimus Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
562,TSC2 A736V TSC2 A736V,Neurofibrosarcoma Neurofibrosarcoma,everolimus Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
563,TSC2 A736V TSC2 A736V,Neurofibrosarcoma Neurofibrosarcoma,temsirolimus Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
564,AKT1 mutation + mTOR mutation AKT1 mutation + mTOR mutation,Leiomyosarcoma Leiomyosarcoma,TAK-228 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
565,IL7R-BCL2 fusion IL7R-BCL2 fusion,Sarcoma Sarcoma,venetoclax Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
566,PML-JAK1 fusion PML-JAK1 fusion,Sarcoma Sarcoma,ruxolitinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
567,TPM4-NTRK3 fusion TPM4-NTRK3 fusion,Sarcoma Sarcoma,larotrectinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
568,TMB-H TMB-H,Leiomyosarcoma Leiomyosarcoma,nivolumab + ipilimumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
569,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,gefitinib + anlotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
570,HER-2 exon 20 insertion HER-2 exon 20 insertion,Non Small Cell Lung Cancer NSCLC,rivoceranib + pyrotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
571,MET amplification + EGFR mutation MET amplification + EGFR mutation,Non Small Cell Lung Cancer NSCLC,EGFR inhibitor + crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
572,MDM4 mutation MDM4 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
573,PD-L1 expression PD-L1 expression,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
574,EGFR mutation + UBXN11 mutation EGFR mutation + UBXN11 mutation,Non Small Cell Lung Cancer NSCLC,erlotinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
575,KRAS G12C + KEAP1 mutation KRAS G12C + KEAP1 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
576,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,GCP Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
577,KRAS mutation KRAS mutation,Non Small Cell Lung Cancer NSCLC,durvalumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
578,BRAF mutation BRAF mutation,Non Small Cell Lung Cancer NSCLC,durvalumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
579,RET fusion RET fusion,Non Small Cell Lung Cancer NSCLC,durvalumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
580,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,durvalumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
581,GPC3 positive GPC3 positive,Hepatocellular Cancer HCC,CAR-T immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
582,ROS1 fusion ROS1 fusion,Non Small Cell Lung Cancer NSCLC,durvalumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
583,NF1 rearrangement NF1 rearrangement,Sarcoma Sarcoma,trametinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
584,FGFR2 translocation FGFR2 translocation,Cholangiocarcinoma Cholangiocarcinoma,ICP-192 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
585,FGFR2 fusion FGFR2 fusion,Cholangiocarcinoma Cholangiocarcinoma,ICP-192 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
586,CD73 expression CD73 expression,Solid Tumor Solid Tumor,atezolizumab SC + TJD5 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
587,FGFR mutation FGFR mutation,Solid Tumor Solid Tumor,ICP-192 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
588,MGMT promoter methylation MGMT promoter methylation,Glioblastoma GBM,ruxolitinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
589,MGMT promoter methylation MGMT promoter methylation,Glioma Glioma,ruxolitinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
590,FGF mutation FGF mutation,Solid Tumor Solid Tumor,ICP-192 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
591,HER-2 mutation HER-2 mutation,Uterine Cancer Uterine Cancer,trastuzumab + pertuzumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
592,FGF19 positive FGF19 positive,Hepatocellular Cancer HCC,H3B-6527 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
593,HER-2 overexpression HER-2 overexpression,Uterine Cancer Uterine Cancer,trastuzumab + pertuzumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
594,ANGPT2-L ANGPT2-L,Hepatocellular Cancer HCC,pembrolizumab + lenvatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
595,TIMP1-L + CCL2-H TIMP1-L + CCL2-H,Hepatocellular Cancer HCC,pembrolizumab + lenvatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
596,PD-L1 expression PD-L1 expression,Biliary Tract Cancer Biliary Tract Cancer,pembrolizumab + lenvatinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
597,HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,trastuzumab + ramucirumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
598,ERBB3 amplification ERBB3 amplification,Uterine Cancer Uterine Cancer,trastuzumab + pertuzumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
599,HER-2 amplification HER-2 amplification,Uterine Cancer Uterine Cancer,trastuzumab + pertuzumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
600,HER-2 positive HER-2 positive,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,trastuzumab + ramucirumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
601,MGMT unmethylation MGMT unmethylation,Glioblastoma GBM,abemaciclib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
602,HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification,Gastric Cancer Gastric Cancer,trastuzumab + ramucirumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
603,BRCA2 mutation BRCA2 mutation,Ovarian Cancer Ovarian Cancer,olaparib + AZD1775 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
604,BRCA1 mutation BRCA1 mutation,Ovarian Cancer Ovarian Cancer,olaparib + AZD1775 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
605,MDM2 mutation MDM2 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
606,TMB-L TMB-L,Non Small Cell Lung Cancer NSCLC,nivolumab + HS-110 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
607,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,nivolumab + HS-110 Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
608,KRAS G12C + STK11 mutation KRAS G12C + STK11 mutation,Non Small Cell Lung Cancer NSCLC,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
609,KRAS G13D KRAS G13D,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
610,KRAS G12S KRAS G12S,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
611,KRAS G12A KRAS G12A,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
612,KRAS G12D KRAS G12D,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
613,ER positive + HER-2 negative ER positive + HER-2 negative,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,CDK6 inhibitor + CDK4 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
614,NRAS Q61L NRAS Q61L,Melanoma Melanoma,trametinib + dabrafenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
615,NRAS Q61R NRAS Q61R,Melanoma Melanoma,trametinib + dabrafenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
616,GNAQ mutation GNAQ mutation,Melanoma Melanoma,trametinib + dabrafenib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
617,TMB-H TMB-H,Melanoma Melanoma,rivoceranib + camrelizumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
618,MDC1 mutation MDC1 mutation,Melanoma Melanoma,rivoceranib + camrelizumab Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
619,LDH-H LDH-H,Melanoma Melanoma,rivoceranib + camrelizumab Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
620,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,gefitinib + anlotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
621,BRAF V600K BRAF V600K,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
622,BRAF V600E BRAF V600E,Melanoma Melanoma,Immunotherapy Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
623,TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p),Chronic Lymphocytic Leukemia CLL,venetoclax + ibrutinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
624,TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p),Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma,venetoclax + ibrutinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
625,EGFR mutation + MET amplification + EGFR amplification EGFR mutation + MET amplification + EGFR amplification,Non Small Cell Lung Cancer NSCLC,EGFR inhibitor + crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
626,EGFR mutation + MET amplification + TP53 mutation EGFR mutation + MET amplification + TP53 mutation,Non Small Cell Lung Cancer NSCLC,EGFR inhibitor + crizotinib Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
627,TP53 mutation TP53 mutation,Mantle Cell Lymphoma Mantle Cell Lymphoma,venetoclax + rituximab + lenalidomide Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
628,ER positive + HER-2 negative ER positive + HER-2 negative,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,CDK6 inhibitor + CDK4 inhibitor Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
629,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,nitroglycerin Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
630,CD5 positive CD5 positive,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,methotrexate IV Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
631,DNMT3A mutation DNMT3A mutation,Non Small Cell Lung Cancer NSCLC,PD-L1 inhibitor Sensitive: C3 – Early Trials  ASCO 2021 - 3 weeks
632,KRAS G12C + STK11 mutation KRAS G12C + STK11 mutation,Lung Adenocarcinoma LUAD,Immunotherapy Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
633,EGFR R776H + EGFR C797S EGFR R776H + EGFR C797S,Non Small Cell Lung Cancer NSCLC,osimertinib Resistant: C3 – Early Trials  ASCO 2021 - 3 weeks
634,MET exon 14 mutation MET exon 14 mutation,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
635,MSH6 F1088fs MSH6 F1088fs,Endometrial Adenocarcinoma Endometrial Adenocarcinoma,pembrolizumab Sensitive: C4 – Case Studies  Oncologist - 3 weeks
636,MET amplification MET amplification,Hepatocellular Cancer HCC,crizotinib Sensitive: C4 – Case Studies  Hepatol Res - 3 weeks
637,NUP98-PRRX1 fusion NUP98-PRRX1 fusion,Acute Myelogenous Leukemia AML,cytarabine + idarubicin Sensitive: C4 – Case Studies  BMC Med Genomics - 3 weeks
638,TMB-H + PD-L1 expression TMB-H + PD-L1 expression,Urothelial Cancer Urothelial Cancer,pembrolizumab Sensitive: C4 – Case Studies  J Oncol Pharm Pract - 3 weeks
639,EGFR exon 19 mutation EGFR exon 19 mutation,Small Cell Lung Cancer Small Cell Lung Cancer,osimertinib Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
640,EGFR exon 21 mutation EGFR exon 21 mutation,Small Cell Lung Cancer Small Cell Lung Cancer,gefitinib Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
641,TGFBR2 mutation TGFBR2 mutation,Non Small Cell Lung Cancer NSCLC,nivolumab Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
642,BRAF mutation + TMB-H BRAF mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
643,ALK mutation + TMB-H ALK mutation + TMB-H,Non Small Cell Lung Cancer NSCLC,Immunotherapy Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
644,EML4-ALK variant 3 EML4-ALK variant 3,Lung Adenocarcinoma LUAD,Angiogenesis inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
645,EML4-ALK variant 3 + TP53 mutation EML4-ALK variant 3 + TP53 mutation,Lung Adenocarcinoma LUAD,alectinib Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
646,EML4-ALK variant 3 EML4-ALK variant 3,Lung Adenocarcinoma LUAD,Immunotherapy Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
647,EML4-ALK variant 3 + TP53 mutation EML4-ALK variant 3 + TP53 mutation,Lung Adenocarcinoma LUAD,brigatinib Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
648,NRAS G12D NRAS G12D,Non Small Cell Lung Cancer NSCLC,bevacizumab + atezolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
649,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,bevacizumab + atezolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
650,GPRC6A-RET fusion + EGFR mutation GPRC6A-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
651,TLN1-RET fusion + EGFR mutation TLN1-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
652,SPECC1-RET fusion + EGFR mutation SPECC1-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
653,TRIM24-RET fusion + EGFR mutation TRIM24-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
654,SHTN1-RET fusion + EGFR mutation SHTN1-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
655,EGFR fusion + PD-L1 overexpression EGFR fusion + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
656,EGFR L747P + PD-L1 overexpression EGFR L747P + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
657,EGFR L861P EGFR L861P,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
658,CCDC6-RET fusion + EGFR mutation CCDC6-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
659,TRIM33-RET fusion + EGFR mutation TRIM33-RET fusion + EGFR mutation,Lung Cancer Lung Cancer,EGFR inhibitor Resistant: C4 – Case Studies  ASCO 2021 - 3 weeks
660,EML4-ALK + ALK-PEX13 EML4-ALK + ALK-PEX13,Sarcoma Sarcoma,crizotinib Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
661,MYH9-ALK + ALK-WDR43 MYH9-ALK + ALK-WDR43,Leiomyosarcoma Leiomyosarcoma,crizotinib Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
662,RANBP2-ALK + TMEM217-ALK RANBP2-ALK + TMEM217-ALK,Sarcoma Sarcoma,crizotinib Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
663,KRAS G12C + PD-L1 overexpression KRAS G12C + PD-L1 overexpression,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
664,NOTCH1 positive + FGFR2 mutation NOTCH1 positive + FGFR2 mutation,Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma,lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
665,BRCA2 mutation BRCA2 mutation,Non Small Cell Lung Cancer NSCLC,JPI-547 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
666,ATM mutation ATM mutation,Breast Cancer Breast Cancer,JPI-547 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
667,PALB2 mutation PALB2 mutation,Endometrial Cancer Endometrial Cancer,rucaparib + E 3810 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
668,SMARCA4 mutation SMARCA4 mutation,Ovarian Cancer Ovarian Cancer,SP2577 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
669,PTEN mutation + STK11 mutation PTEN mutation + STK11 mutation,Breast Cancer Breast Cancer,TAK-228 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
670,PTEN mutation + TSC1 mutation PTEN mutation + TSC1 mutation,Leiomyosarcoma Leiomyosarcoma,TAK-228 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
671,NF1 mutation NF1 mutation,Leiomyosarcoma Leiomyosarcoma,IPN60090 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
672,HR positive HR positive,HER2 Negative Breast Cancer HER2 Negative Breast Cancer,RBN-2397 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
673,AKT1 mutation + mTOR mutation AKT1 mutation + mTOR mutation,Endometrial Cancer Endometrial Cancer,TAK-228 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
674,AKT1 mutation + mTOR mutation AKT1 mutation + mTOR mutation,Breast Cancer Breast Cancer,TAK-228 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
675,TMB-H + MSH6 F1088fs TMB-H + MSH6 F1088fs,Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma,pembrolizumab Sensitive: C4 – Case Studies  The Oncologist - 3 weeks
676,PD-L1 expression + TMB-H PD-L1 expression + TMB-H,Bladder Cancer Bladder Cancer,pembrolizumab Sensitive: C4 – Case Studies  J Oncol Pharm Pract - 3 weeks
677,BRCA2 mutation BRCA2 mutation,Breast Cancer Breast Cancer,JPI-547 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
678,BRCA1 mutation BRCA1 mutation,Breast Cancer Breast Cancer,JPI-547 Sensitive: C4 – Case Studies  ASCO 2021 - 3 weeks
679,MSI-H/dMMR + TMB-H + PD-L1 negative MSI-H/dMMR + TMB-H + PD-L1 negative,Uterine Cancer Uterine Cancer,pembrolizumab Sensitive: C4 – Case Studies  The Oncologist - 3 weeks
680,SETBP1 mutation + NRAS mutation SETBP1 mutation + NRAS mutation,Juvenile Myelomonocytic Leukemia Juvenile Myelomonocytic Leukemia,trametinib Sensitive: D – Preclinical  Leukemia - 3 weeks
681,ETV1 P159S ETV1 P159S,Small Cell Lung Cancer Small Cell Lung Cancer,osimertinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
682,ETV1 E462Q ETV1 E462Q,Small Cell Lung Cancer Small Cell Lung Cancer,osimertinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
683,ETV1 P159S ETV1 P159S,Small Cell Lung Cancer Small Cell Lung Cancer,gefitinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
684,ETV1 E462Q ETV1 E462Q,Small Cell Lung Cancer Small Cell Lung Cancer,gefitinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
685,ITGA4 negative ITGA4 negative,Chronic Lymphocytic Leukemia CLL,lenalidomide Sensitive: D – Preclinical  Hematol Oncol - 3 weeks
686,EML4-ALK variant 3 + TP53 mutation EML4-ALK variant 3 + TP53 mutation,Lung Adenocarcinoma LUAD,lorlatinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
687,EML4-ALK variant 3 + TP53 mutation EML4-ALK variant 3 + TP53 mutation,Lung Adenocarcinoma LUAD,crizotinib Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
688,ALK C1156Y + I1171T ALK C1156Y + I1171T,Lung Adenocarcinoma LUAD,crizotinib Resistant: D – Preclinical  ASCO 2021 - 3 weeks
689,ALK C1156Y + I1171T ALK C1156Y + I1171T,Lung Adenocarcinoma LUAD,ceritinib Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
690,miR-503-5p overexpression miR-503-5p overexpression,Triple Negative Breast Cancer Triple Negative Breast Cancer,doxorubicin hydrochloride Resistant: D – Preclinical  ASCO 2021 - 3 weeks
691,EWSR1-WT1 fusion EWSR1-WT1 fusion,Soft Tissue Sarcoma Soft Tissue Sarcoma,trabectedin Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
692,PTGR1 elevation + HRD PTGR1 elevation + HRD,Prostate Cancer Prostate Cancer,LP-184 Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
693,PTGR1 elevation + HRD PTGR1 elevation + HRD,Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma,LP-184 Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
694,PTGR1 elevation + HRD PTGR1 elevation + HRD,Lung Adenocarcinoma LUAD,LP-184 Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
695,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,trastuzumab + evolocumab Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
696,CD38 expression CD38 expression,Multiple Myeloma Multiple Myeloma,ISB 1342 Sensitive: D – Preclinical  ASCO 2021 - 3 weeks
697,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,pomalidomide + elotuzumab Sensitive: A1 - Approval
698,No biomarker No biomarker,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,lisocabtagene maraleucel Sensitive: A1 - Approval
699,CD20 positive CD20 positive,Chronic Lymphocytic Leukemia CLL,Truxima (rituximab biosimilar) Sensitive: A1 - Approval
700,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,afatinib Sensitive: A1 - Approval
701,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,ramucirumab Sensitive: A1 - Approval
702,ALK positive ALK positive,Non Small Cell Lung Cancer NSCLC,lorlatinib Sensitive: A1 - Approval
703,EGFR exon 19 deletion EGFR exon 19 deletion,Non Small Cell Lung Cancer NSCLC,gefitinib Sensitive: A1 - Approval
704,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,afatinib Sensitive: A1 - Approval
705,ALK positive ALK positive,Non Small Cell Lung Cancer NSCLC,alectinib Sensitive: A1 - Approval
706,KIT positive KIT positive,Gastrointestinal Stromal Tumor GIST,imatinib Sensitive: A1 - Approval
707,HER-2 positive HER-2 positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,margetuximab Sensitive: A1 - Approval
708,ALK fusion ALK fusion,Non Small Cell Lung Cancer NSCLC,brigatinib Sensitive: A1 - Approval
709,No biomarker No biomarker,Follicular Lymphoma Follicular Lymphoma,axicabtagene ciloleucel Sensitive: A1 - Approval
710,No biomarker No biomarker,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,axicabtagene ciloleucel Sensitive: A1 - Approval
711,No biomarker No biomarker,Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma,axicabtagene ciloleucel Sensitive: A1 - Approval
712,PDGFRA D842V PDGFRA D842V,Gastrointestinal Stromal Tumor GIST,avapritinib Sensitive: A1 - Approval
713,No biomarker No biomarker,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,nivolumab Sensitive: A1 - Approval
714,No biomarker No biomarker,Fallopian Tube Cancer Fallopian Tube Cancer,niraparib Sensitive: A1 - Approval
715,No biomarker No biomarker,Ovarian Cancer Ovarian Cancer,niraparib Sensitive: A1 - Approval
716,No biomarker No biomarker,Peritoneal Cancer Peritoneal Cancer,niraparib Sensitive: A1 - Approval
717,No biomarker No biomarker,Mantle Cell Lymphoma Mantle Cell Lymphoma,brexucabtagene autoleucel Sensitive: A1 - Approval
718,No biomarker No biomarker,Non-Hodgkin’s Lymphoma NHL,brentuximab vedotin Sensitive: A1 - Approval
719,ROS1 fusion ROS1 fusion,Non Small Cell Lung Cancer NSCLC,entrectinib Sensitive: A1 - Approval
720,No biomarker No biomarker,Gastric Cancer Gastric Cancer,nivolumab Sensitive: A1 - Approval
721,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,bevacizumab Sensitive: A1 - Approval
722,ALK positive ALK positive,Non-Hodgkin’s Lymphoma NHL,crizotinib Sensitive: A1 - Approval
723,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,nivolumab + ipilimumab Sensitive: A1 - Approval
724,No biomarker No biomarker,Small Cell Lung Cancer Small Cell Lung Cancer,durvalumab Sensitive: A1 - Approval
725,EGFR T790M EGFR T790M,Non Small Cell Lung Cancer NSCLC,lazertinib Sensitive: A1 - Approval
726,No biomarker No biomarker,Squamous Cell Carcinoma of Head and Neck SCCHN,cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
727,No biomarker No biomarker,Gastric Adenocarcinoma Gastric Adenocarcinoma,cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
728,No biomarker No biomarker,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
729,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,cisplatin + pemetrexed Sensitive: A1 - Approval
730,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,DP Sensitive: A1 - Approval
731,No biomarker No biomarker,Breast Cancer Breast Cancer,docetaxel + doxorubicin hydrochloride + cyclophosphamide intravenous Sensitive: A1 - Approval
732,No biomarker No biomarker,Basal Cell Carcinoma BCC,fluorouracil topical Sensitive: A1 - Approval
733,EGFR mutation EGFR mutation,Non Small Cell Lung Cancer NSCLC,gefitinib Sensitive: A1 - Approval
734,EGFR L858R EGFR L858R,Non Small Cell Lung Cancer NSCLC,gefitinib Sensitive: A1 - Approval
735,No biomarker No biomarker,Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer,cisplatin Sensitive: A1 - Approval
736,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,carfilzomib Sensitive: A1 - Approval
737,No biomarker No biomarker,Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma,cabozantinib capsule Sensitive: A1 - Approval
738,ALK positive ALK positive,Non Small Cell Lung Cancer NSCLC,crizotinib Sensitive: A1 - Approval
739,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,pembrolizumab Sensitive: A1 - Approval
740,ROS1 positive ROS1 positive,Non Small Cell Lung Cancer NSCLC,crizotinib Sensitive: A1 - Approval
741,No biomarker No biomarker,Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer,atezolizumab Sensitive: A1 - Approval
742,No biomarker No biomarker,Small Cell Lung Cancer Small Cell Lung Cancer,atezolizumab Sensitive: A1 - Approval
743,BRCA2 mutation BRCA2 mutation,Pancreatic Cancer Pancreatic Cancer,olaparib Sensitive: A1 - Approval
744,PD-L1 expression PD-L1 expression,Non Small Cell Lung Cancer NSCLC,durvalumab Sensitive: A1 - Approval
745,IDH2 mutation IDH2 mutation,Acute Myelogenous Leukemia AML,enasidenib Sensitive: A1 - Approval
746,No biomarker No biomarker,Acute Myelogenous Leukemia AML,glasdegib Sensitive: A1 - Approval
747,No biomarker No biomarker,Hepatocellular Cancer HCC,pembrolizumab Sensitive: A1 - Approval
748,No biomarker No biomarker,Hepatocellular Cancer HCC,bevacizumab + atezolizumab Sensitive: A1 - Approval
749,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,bortezomib + panobinostat Sensitive: A1 - Approval
750,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
751,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,bortezomib Sensitive: A1 - Approval
752,BRCA1 mutation BRCA1 mutation,Pancreatic Cancer Pancreatic Cancer,olaparib Sensitive: A1 - Approval
753,No biomarker No biomarker,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,rituximab Sensitive: A1 - Approval
754,RET fusion RET fusion,Thyroid Gland Carcinoma Thyroid Gland Carcinoma,pralsetinib Sensitive: A1 - Approval
755,No biomarker No biomarker,Lymphoma Lymphoma,axicabtagene ciloleucel Resistant: A1 - Approval
756,No biomarker No biomarker,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,tisagenlecleucel-T Sensitive: A1 - Approval
757,No biomarker No biomarker,B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia,tisagenlecleucel-T Sensitive: A1 - Approval
758,No biomarker No biomarker,Childhood B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia,tisagenlecleucel-T Sensitive: A1 - Approval
759,No biomarker No biomarker,Prostate Cancer Prostate Cancer,apalutamide Sensitive: A1 - Approval
760,No biomarker No biomarker,Chronic Lymphocytic Leukemia CLL,rituximab + ibrutinib Sensitive: A1 - Approval
761,No biomarker No biomarker,Squamous Cell Carcinoma of Head and Neck SCCHN,nivolumab Sensitive: A1 - Approval
762,No biomarker No biomarker,Acute Myelogenous Leukemia AML,azacitidine oral Sensitive: A1 - Approval
763,No biomarker No biomarker,Non Small Cell Lung Cancer NSCLC,DP Sensitive: A1 - Approval
764,No biomarker No biomarker,Gastric Cancer Gastric Cancer,TPF Sensitive: A1 - Approval
765,No biomarker No biomarker,Urothelial Cancer Urothelial Cancer,avelumab Sensitive: A1 - Approval
766,BRCA1 mutation BRCA1 mutation,Peritoneal Cancer Peritoneal Cancer,bevacizumab + olaparib Sensitive: A1 - Approval
767,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,SVd Sensitive: A1 - Approval
768,No biomarker No biomarker,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,TPF Sensitive: A1 - Approval
769,No biomarker No biomarker,Squamous Cell Carcinoma of Head and Neck SCCHN,TPF Sensitive: A1 - Approval
770,PD-L1 expression PD-L1 expression,Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma,pembrolizumab Sensitive: A1 - Approval
771,No biomarker No biomarker,Acute Myelogenous Leukemia AML,cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval
772,BRAF V600 BRAF V600,Melanoma Melanoma,vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
773,BRAF V600E BRAF V600E,Colorectal Cancer CRC,cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
774,No biomarker No biomarker,Soft Tissue Sarcoma Soft Tissue Sarcoma,olaratumab Sensitive: A1 - Approval
775,No biomarker No biomarker,Colon Cancer Colon Cancer,capecitabine Sensitive: A1 - Approval
776,Chr del(17p) Chr del(17p),Chronic Lymphocytic Leukemia CLL,venetoclax + obinutuzumab Sensitive: A1 - Approval
777,TP53 mutation TP53 mutation,Chronic Lymphocytic Leukemia CLL,venetoclax + obinutuzumab Sensitive: A1 - Approval
778,No biomarker No biomarker,Chronic Lymphocytic Leukemia CLL,venetoclax + obinutuzumab Sensitive: A1 - Approval
779,BCR-ABL1 fusion BCR-ABL1 fusion,Chronic Myeloid Leukemia CML,dasatinib Sensitive: A1 - Approval
780,No biomarker No biomarker,Rectal Cancer Rectal Cancer,FOLFIRI Sensitive: A1 - Approval
781,No biomarker No biomarker,Breast Cancer Breast Cancer,TAC Sensitive: A1 - Approval
782,HR positive HR positive,HER2 Positive Breast Cancer HER2 Positive Breast Cancer,neratinib Sensitive: A1 - Approval
783,No biomarker No biomarker,Urothelial Cancer Urothelial Cancer,sacituzumab govitecan-hziy Sensitive: A1 - Approval
784,No biomarker No biomarker,Colon Cancer Colon Cancer,5-fluorouracil + irinotecan Sensitive: A1 - Approval
785,No biomarker No biomarker,Multiple Myeloma Multiple Myeloma,pomalidomide Sensitive: A1 - Approval
786,CD20 positive CD20 positive,Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma,Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
787,PD-L1 expression PD-L1 expression,Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma,pembrolizumab Sensitive: A1 - Approval
788,PD-L1 expression PD-L1 expression,Renal Cell Carcinoma RCC,avelumab + axitinib Sensitive: A1 - Approval
